Malta - English - Medicines Authority

boehringer ingelheim international gmbh binger strasse 173, 55216 ingelheim am rhein, germany - alteplase - powder and solvent for solution for infusion or injection - alteplase 10 mg - antithrombotic agents

Malta - English - Medicines Authority

boehringer ingelheim international gmbh binger strasse 173, 55216 ingelheim am rhein, germany - ipratropium bromide - pressurised inhalation, solution - ipratropium bromide 20 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

boehringer ingelheim international gmbh binger strasse 173, 55216 ingelheim am rhein, germany - ipratropium bromide - nebuliser solution - ipratropium bromide 500 µg - drugs for obstructive airway diseases

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - nevirapine - suspension - 50 mg/5 ml

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - recombinant human tissue-type plasminogen activator - injection, powder, for solution - 50 mg/vial - recombinant human tissue-type plasminogen activator 50 mg/vial

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin - film coated tablets - linagliptin 5 mg - linagliptin - linagliptin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. trajenta should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 150 mg - dabigatran etexilate - dabigatran etexilate - prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - tiotropium; olodaterol - inhalation solution - 2.5 µg/2.5 microgram(s) - anticholinergics; anticholinergics - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - it is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - linagliptin (unii: 3x29zej4r2) (linagliptin - unii:3x29zej4r2), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - linagliptin 2.5 mg - jentadueto xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use jentadueto xr is not recommended in patients with type 1 diabetes mellitus. jentadueto xr has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using jentadueto xr [see warnings and precautions (5.2)]. jentadueto xr is contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m2 ) [see warnings and precautions (5.1)]. - acute or chronic metabolic acidosis, including diabetic ketoacidosis [see warnings and precautions (5.1)]. - hypersensitivity to linagliptin, metformin, or any of the excipients in jentadueto xr, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred with linagliptin [see warnings and precautions (5.4) and adve

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u) - empagliflozin 10 mg - jardiance is indicated: - to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. - to reduce the risk of sustained decline in egfr, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. - to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. - as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. limitations of use jardiance is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.1)] . jardiance is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an egfr less than 30 ml/min/1.73 m2 . jardiance is likely to be ineffective in t